Tags : teriparatide

Biosimilars

EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s

Shots: The CHMP has adopted the positive opinion recommending the approval of Theramex’s  Livogiva (biosimilar, teriparatide) intended for the treatment of osteoporosis and will be available as a solution for injection (20 micrograms/80 microliters) The CHMP has also recommend marketing authorization to EuroGenerics’ Qutavina (biosimilar, teriparatide) to treat osteoporosis, also available as a solution for […]Read More

Biosimilars

Daewon Pharmaceutical Launches its Terrosa (biosimilar, teriparatide) to Treat Osteoporosis

Shots: Terrosa is a parathyroid hormone (PTH) gene recombination candidate originally developed by Richter-Helm Biotec to treat osteoporosis in men and postmenopausal women including those at high risk of fracture. Additionally, Terrosa has completed its P-I and P-III trials in EU and Japan has shown an increase in bone density in the spine, femur, and […]Read More

Biosimilars

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies

Shots: Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories PF708 is a biosimilar referencing Eli Lilly’s […]Read More

Biosimilars

Gedeon Richter Launches Terrosa (biosimilar, teriparatide) in Europe

Shots: Richter has launched Terrosa, a biosimilar to Eli Lilly’s Forsteo approved for osteoporosis in postmenopausal women and in men at high risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture Richter launched Terrosa through its affiliates in Europe following the patent […]Read More